Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Early menopause

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    135 result(s) found for: Early menopause. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2007-005109-23 Sponsor Protocol Number: AWC LowE Start Date*: 2009-08-05
    Sponsor Name:Uppsala University Hospital
    Full Title: Low-Dose Hormone Therapy Initiated early after Menopause and Changes in Artery Wall Composition (AWC), as Assesssed by High-Frequency Ultrasound.
    Medical condition: Age/menopause related changes in the artery wall composition after menopause
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003601 Atherosclerosis LLT
    9.1 10051775 Postmenopause LLT
    9.1 10020388 Hormone replacement therapy LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003813-92 Sponsor Protocol Number: EPT02/2016 Start Date*: 2017-01-25
    Sponsor Name:IBSA FARMACEUTICI ITALIA SRL
    Full Title: Open clinical trial to evaluate the efficacy of intravesical instillation of hyaluronate added to early instillation of mitomycin vs early instillation of mitomycin in patients suffering from low r...
    Medical condition: Low risk not muscle-infiltrating bladder neoplasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005328-17 Sponsor Protocol Number: MO28048 Start Date*: 2012-04-26
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase III prospective, two-cohort non-randomised, multi-centre, multinational, open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in pati...
    Medical condition: HER2-positive primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) CZ (Completed) DE (Completed) ES (Completed) FR (Completed) HU (Completed) PT (Completed) GB (Completed) NO (Completed) IT (Completed) GR (Completed) LT (Completed) PL (Completed) SI (Completed) SK (Completed) FI (Completed) BG (Completed) NL (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002578-20 Sponsor Protocol Number: ESN364_HF_204 Start Date*: 2015-08-25
    Sponsor Name:Euroscreen S.A
    Full Title: Pilot/Phase IIa Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes
    Medical condition: hot flashes
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10020407 Hot flashes LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-009862-15 Sponsor Protocol Number: D3191C00009 Start Date*: 2009-05-25
    Sponsor Name:AstraZeneca AB, European Regulatory Affairs
    Full Title: A double-Blind, Randomised, Placebo-Controlled, Multicentre, Dose-Escalating Study of AZD1305 Given Intravenously for Cardioversion of Atrial Fibrillation
    Medical condition: Atrial fibrillation clinically indicated for cardioversion.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003658 Atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) HU (Prematurely Ended) DK (Prematurely Ended) SE (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004455-29 Sponsor Protocol Number: 112115 Start Date*: 2008-12-05
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, randomized, multicentre, observer-blind study to compare and characterize the immunoginicity and safety parameters induced by various GSK Biologicals’ Adjuvant Systems in combination wi...
    Medical condition: Hepatitis B surface antigen (HBsAg) vaccine administred in HBV naïve adult subjects aged between 18 and 45 years old, inclusive, in good general health.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004517-84 Sponsor Protocol Number: ITFE-2026-C10 Start Date*: 2015-02-26
    Sponsor Name:ITF Research Pharma S.L.U
    Full Title: A PHASE II PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND MULTI-CENTRE CLINICAL TRIAL TO ASSESS THE SAFETY OF 0.005 % ESTRIOL VAGINAL GEL IN HORMONE RECEPTOR-POSITIVE POSTMENOPAUSAL ...
    Medical condition: In postmenopausal hormone receptor positive breast cancer, treatment with aromatase inhibitors is the most effective and well-studied therapy. Lack of adherence is common due to the side-effects; v...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001559-38 Sponsor Protocol Number: GEICAM/2018-06 Start Date*: 2022-01-20
    Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)
    Full Title: A Randomized Phase II Study to Evaluate the Incidence of Discontinuations due to Diarrhoea at 3 Cycles in patients with Early-stage HER2-positive (HER2+), Hormone Receptor-positive (HR+) Breast Can...
    Medical condition: HER2+, HR+ Early stage Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083234 Hormone receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-007345-31 Sponsor Protocol Number: 3144A2-3004-WW Start Date*: 2009-08-05
    Sponsor Name:Puma Biotechnology, Inc
    Full Title: A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer.
    Medical condition: Her2 overexpressed, early stage breast cancer (adjuvant treatment stage)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10006173 Breast adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) DE (Completed) IT (Completed) SK (Completed) CZ (Completed) ES (Completed) BE (Completed) GB (Completed) LT (Completed) NL (Completed) FR (Completed) DK (Completed) SE (Completed) GR (Completed) MT (Completed) BG (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000576-13 Sponsor Protocol Number: INO102141 Start Date*: 2004-11-03
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A two-centre, randomised, double-blind, double-dummy, placebo-controlled, 3-period cross-over study to evaluate the effect of treatment with repeat doses of GW274150 on the allergen-induced late as...
    Medical condition: Mild asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002007-33 Sponsor Protocol Number: A2581078 Start Date*: 2004-11-25
    Sponsor Name:Pfizer Inc.
    Full Title: An 80-week, randomized, multi center, parallel group, double-blind study of the efficacy and safety of atorvastatin 80 mg plus an acetylcholinesterase inhibitor versus an acetylcholinesterase inhib...
    Medical condition: Alzheimer Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000123-39 Sponsor Protocol Number: VITACTOH Start Date*: 2020-04-02
    Sponsor Name:Fundación Investigación Biomédica Hospital Ramón y Cajal
    Full Title: Phase II clinical trial, randomized, double blind, masked, controlled with physiological serum about the efficacy of intravenous administration of vitamin C during the anhepatic phase of liver tran...
    Medical condition: Reperfusion syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012019-17 Sponsor Protocol Number: BO22280 Start Date*: 2009-09-02
    Sponsor Name:F. Hoffmann - La Roche Ltd
    Full Title: A randomised, multicentre, multinational Phase II study to evaluate pertuzumab in combination with trastuzumab given either concomitantly or sequentially with standard anthracycline based chemother...
    Medical condition: Locally advanced, inflammatory or early stage HER2-positive breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) DE (Completed) GB (Completed) PT (Completed) GR (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004374-15 Sponsor Protocol Number: PUMA-NER-6201 Start Date*: 2018-04-13
    Sponsor Name:Puma Biotechnology, Inc.
    Full Title: An Open Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis
    Medical condition: Early Stage HER2+ Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001344-22 Sponsor Protocol Number: 116640 Start Date*: 2013-02-19
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, randomised, single-blind study to develop read-outs aimed at detecting and characterising the early and adaptive immune responses and to evaluate the kinetics of the early response and ...
    Medical condition: Healthy volunteers (Hepatitis B surface antigen (HBsAg) vaccine administered in hepatitis B virus (HBV) naive adult subjects aged between 18 and 45 years old, inclusive, in good general health.)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016523-61 Sponsor Protocol Number: PJMR0062105 Start Date*: 2009-12-07
    Sponsor Name:King’s College London [...]
    1. King’s College London
    2. Guy's & St Thomas NHS Trust
    Full Title: 18F-fluoride PET for Early Non-invasive Assessment of Cortical Bone Formation
    Medical condition: Osteopenia Please note this is not a study to investigate the use of the IMP for the treatment of osteopenia but rather to validate a non-invasive imaging technique for measuring early changes in b...
    Disease: Version SOC Term Classification Code Term Level
    12 10049088 Osteopenia LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001976-39 Sponsor Protocol Number: GORTEC-2018-02 Start Date*: 2018-12-14
    Sponsor Name:GORTEC
    Full Title: A phase II trial of radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck
    Medical condition: Untreated Squamous cell carcinoma : Oral cavity, oropharynx, hypopharynx or larynx
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001295-36 Sponsor Protocol Number: SRM105106 Start Date*: 2007-08-22
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A parallel-group, double-blind, randomized, placebo-controlled, active comparator, multicenter study to evaluate the efficacy, safety, tolerability and pharmacokinetics of two doses of GSK232802 ad...
    Medical condition: Treatment of moderate to extremely severe vasomotor symptoms in healthy postmenopausal women
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-004241-36 Sponsor Protocol Number: ML42502 Start Date*: 2021-03-23
    Sponsor Name:Roche Farma S.A
    Full Title: TIME AND MOTION STUDY OF A SUBCUTANEOUS FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR THE TREATMENT OF PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER.
    Medical condition: EARLY BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003682-26 Sponsor Protocol Number: CF101-301RA Start Date*: 2019-07-11
    Sponsor Name:Can-Fite BioPharma, Ltd.
    Full Title: A Phase 3, Randomized, Double-Blind, Active- and Placebo controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of CF101 Compared to Methotrexate in the Treatment of Early Rheumatoid ...
    Medical condition: Early Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) RO (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 13 06:48:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA